Literature DB >> 30952518

Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer? - National Survey.

Arman Zereshkian1, Xingshan Cao2, Martine Puts3, Krista Dawdy2, Lisa Di Prospero4, Shabbir Alibhai5, Matthew Neve6, Ewa Szumacher7.   

Abstract

PURPOSE: Clinical judgement may not be sufficient to detect relevant problems in older cancer patients. We investigated what Geriatric Assessment tools (GA) are used by Canadian radiation oncologists (CROs) to treat non-metastatic prostate cancer patients aged 80 years and older.
METHODS: A 27-item cross-sectional survey was developed with input from a multidisciplinary team and distributed electronically to Genitourinary (GU) CROs via LimeSurvey. Survey contents included: demographics, treatment choice based on components of GA, and how GA tools are used in clinic. Descriptive statistics were used to analyze multiple-choice data, with Open-ended question being coded and analyzed for emerging themes.
RESULTS: 154 GU CRO's were contacted, 44 responded (29%). Active surveillance was the choice of therapy in older low risk prostate cancer patients regardless of factors used in a GA assessment (97%). Results in intermediate and high-risk older prostate cancer patients were more heterogenous. Functional status and comorbidities were the most important factor in the decision-making-process (94%, 91%). Sixty-six percent of CROs did not use any GA tools; yet 77% felt comfortable to very comfortable treating older patients. Eighty-eight percent felt there were some to very few guidelines in helping them to treat older patients. Barriers to using GA included lack of knowledge, time, support, and resources.
CONCLUSIONS: GAs are not commonly utilized by CROs. Majority of CROs felt comfortable treating older patients with prostate cancer, regardless of guidelines/evidence in this population. This may have negative implications on patient care. CROs are however open to referring patients for a formal GA.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Year:  2019        PMID: 30952518     DOI: 10.1016/j.jgo.2019.01.015

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  5 in total

1.  A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.

Authors:  A Holmes; B D Kelly; M Perera; R S Eapen; D M Bolton; N Lawrentschuk
Journal:  World J Urol       Date:  2020-06-04       Impact factor: 4.226

Review 2.  The Evolution of Geriatric Oncology and Geriatric Assessment over the Past Decade.

Authors:  Darryl Outlaw; Maya Abdallah; Luiz A Gil-Jr; Smith Giri; Tina Hsu; Jessica L Krok-Schoen; Gabor Liposits; Tânia Madureira; Joana Marinho; Ishwaria M Subbiah; Gina Tuch; Grant R Williams
Journal:  Semin Radiat Oncol       Date:  2022-04       Impact factor: 5.934

3.  The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study.

Authors:  Szu-Yuan Wu; Fransisca Fortunata Effendi; Ricardo E Canales; Chung-Chien Huang
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

4.  Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Szu-Yuan Wu; Fransisca Fortunata Effendi; Jhao Yang Peng; Chung-Chien Huang
Journal:  Front Med (Lausanne)       Date:  2022-05-03

5.  International Survey on Frailty Assessment in Patients with Cancer.

Authors:  Giuseppe Luigi Banna; Ornella Cantale; Maria Monica Haydock; Nicolò Matteo Luca Battisti; Kevin Bambury; Naja Musolino; Eoin O'Carroll; Giuseppe Maltese; Lucia Garetto; Alfredo Addeo; Fabio Gomes
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.